An interventional study of Physical Frailty Intervention Module (PFIM) in Frailty and Hypertension (HTN), sponsored by Dong Yuan. Not yet recruiting at 3 sites in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Dong Yuan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Frailty with a site in China — 26 open to participants now, 28 under way, none of them phase 3. Frailty · China.
Among the 65 studies in Frailty with a site in China, this one is the 18th largest by planned enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2026, is one of 26 with no phase, reaches primary completion later than 17 of the 27 other live ones, and was the 65th registered.
1,288 studies on the registry are indexed under Frailty; 455 are open to participants now.
Browse Frailty studies →26 of the 65 studies in Frailty with a site in China are open now. Recruiting first, the newest first:
Guangdong Provincial People's Hospital · Sites in China
Ages 75+
Jiawei Jiang · Sites in China
Ages 60–85
Huashan Hospital · Sites in China
Ages 61+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
Lanyue Zhu · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 1 · Phase 4 2
First in 2013; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 82 across 770 interventional studies indexed under Frailty.
Median enrollment 146 across the 32 interventional studies, 500 across the 33 observational. Of the 27 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 65 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dong Yuan as lead sponsor.
Dong Yuan has 1 study filed under Frailty — fewer than ten, so there is no comparison to draw.
8 of the studies in Frailty with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05635877Yongtao SunEffects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients | 2026-11-30 |
| NCT06765499First People's Hospital of HangzhouThe Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease | 2026-12-30 |
| NCT07845656Jiawei JiangA Home-based Multicomponent Exercise Intervention Program Based on the Fogg Behavior Model (FBM) for Older Adults With Osteosarcopenia and Frailty | 2026-12-31 |
| NCT07030179Lanyue ZhuThe Relationship Between Preoperative Frailty and Postoperative AKI and the Mediating Effect of Intraoperative BP | 2026-12-31 |
| NCT05598112Chinese Academy of Medical Sciences, Fuwai HospitalEffect of Gut Microbiome Intervention on Aging Via Oral FMT | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Frailty with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Physical frailty is a common health concern among older adults with hypertension and may contribute to reduced physical function, loss of independence, and poorer quality of life. This study aims to evaluate the effectiveness of a 12-week nurse-led Physical Frailty Intervention Module (PFIM) among community-dwelling older adults with hypertension and physical frailty in Shandong Province, China.
This nonrandomized controlled study will recruit 124 participants aged 60 years or older from three primary healthcare institutions. Two institutions will be assigned to the intervention group, which will receive the PFIM in addition to usual care, while one institution will serve as the control group and provide usual care only.
The PFIM is based on the Health Action Process Approach (HAPA) and combines simplified Baduanjin exercise, basic nutrition guidance, hypertension self-management education, and behavioral support. The intervention includes nurse-led group sessions, individualized home-based exercise, and follow-up support over 12 weeks.
Physical frailty will be the primary outcome. Physical performance, nutritional status, health literacy, perceived social support, depressive symptoms, and quality of life will be assessed as secondary outcomes at baseline and after 12 weeks.
This study is the third phase of a multiphase research project involving the development, validation, and evaluation of a Physical Frailty Intervention Module (PFIM) for older adults with hypertension and physical frailty.
A pragmatic, two-arm, nonrandomized controlled quasi-experimental design will be used. The study will be conducted at three primary healthcare institutions in Yanzhou District, Jining, Shandong Province, China. Two institutions will be allocated to the intervention group and one to the control group to minimize contamination. The planned sample size is 124 participants, with 62 participants per group.
The 12-week PFIM is informed by the Health Action Process Approach (HAPA) and delivered by trained nurses. It comprises three stages:
Weeks 1-4 focus on motivation and participation preparation through weekly face-to-face group education sessions addressing physical frailty, hypertension, nutrition, exercise safety, and behavioral change.
Weeks 5-8 emphasize action planning and behavior initiation through weekly group sessions and home-based simplified Baduanjin practice two to three times weekly for 15-20 minutes per session.
Weeks 9-12 focus on behavior maintenance through continued home practice, progressing toward 20-30 minutes per session when appropriate, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11.
Standing or seated simplified Baduanjin exercises will be assigned according to participants' physical performance and clinical safety assessments. The control group will receive usual hypertension care without the structured PFIM.
The primary outcome is physical frailty severity, measured using the FRAIL Scale. Secondary outcomes include physical performance (SPPB), nutritional status (MNA-SF), health literacy (HLS-SF12), perceived social support (PSSS), depressive symptoms (GDS-15), and quality of life (OPQOL-brief). Outcomes will be assessed at baseline and immediately after the 12-week intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive the 12-week nurse-led Physical Frailty Intervention Module (PFIM) in addition to usual primary healthcare for hypertension. The intervention includes simplified Baduanjin exercise, nutrition guidance, hypertension self-management education, individualized action planning, self-monitoring, and follow-up support.
Behavioral: Physical Frailty Intervention Module (PFIM)
Participants in the control group will receive usual primary healthcare for hypertension, including routine blood pressure monitoring, medication management, general lifestyle advice, and regular follow-up. No structured Physical Frailty Intervention Module (PFIM) will be provided during the 12-week study period.
The Physical Frailty Intervention Module (PFIM) is a 12-week nurse-led behavioral intervention based on the Health Action Process Approach (HAPA). During Weeks 1-4, participants attend weekly group education sessions on physical frailty, hypertension, nutrition, and exercise safety. During Weeks 5-8, participants attend weekly group sessions and begin home-based simplified Baduanjin practice 2-3 times per week for 15-20 minutes per session. During Weeks 9-12, home practice continues, progressing toward 20-30 minutes per session as tolerated, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11. Standing or seated exercises are assigned according to physical performance and safety assessments. The intervention is provided in addition to usual hypertension care.
Change in Physical Frailty Severity Measured by the FRAIL Scale
Physical frailty will be assessed using the five-item FRAIL Scale, covering fatigue, resistance, ambulation, illnesses, and weight loss. Each item is scored 0 or 1, yielding a total score from 0 to 5. Higher scores indicate greater frailty severity. Change will be calculated as the Week 12 score minus the baseline score.
Time frame: Baseline (Week 0) and Week 12
Change in Physical Performance Measured by the Short Physical Performance Battery (SPPB)
Physical performance will be assessed using the Short Physical Performance Battery (SPPB), comprising balance, 4-meter gait speed, and repeated chair stands. Each component is scored from 0 to 4, yielding a total score from 0 to 12. Higher scores indicate better physical performance. Change is the Week 12 score minus the baseline score.
Time frame: Baseline (Week 0) and Week 12
Change in Nutritional Status Measured by the Mini Nutritional Assessment-Short Form (MNA-SF)
Nutritional status will be assessed using the six-item Mini Nutritional Assessment-Short Form (MNA-SF). Total scores range from 0 to 14, with higher scores indicating better nutritional status. Change is the Week 12 score minus the baseline score.
Time frame: Baseline (Week 0) and Week 12
Change in Health Literacy Measured by the Health Literacy Survey-Short Form 12 (HLS-SF12)
Health literacy will be measured using the 12-item Health Literacy Survey-Short Form (HLS-SF12), covering healthcare, disease prevention, and health promotion. Responses are converted to a standardized index ranging from 0 to 50. Higher scores indicate better health literacy. Change is the Week 12 index minus the baseline index.
Time frame: Baseline (Week 0) and Week 12
Change in Perceived Social Support Measured by the Perceived Social Support Scale (PSSS)
Perceived social support will be assessed using the 12-item Perceived Social Support Scale (PSSS), covering support from family, friends, and significant others. Each item is rated from 1 to 7, giving a total score from 12 to 84. Higher scores indicate greater perceived social support. Change is the Week 12 score minus the baseline score.
Time frame: Baseline (Week 0) and Week 12
Change in Depressive Symptoms Measured by the 15-Item Geriatric Depression Scale (GDS-15)
Depressive symptoms will be assessed using the 15-item Geriatric Depression Scale (GDS-15). Each item is scored 0 or 1, giving a total score from 0 to 15. Higher scores indicate more severe depressive symptoms. Change is the Week 12 score minus the baseline score.
Time frame: Baseline (Week 0) and Week 12
Change in Quality of Life Measured by the Brief Older People's Quality of Life Questionnaire (OPQOL-brief)
Quality of life will be assessed using the 13-item Brief Older People's Quality of Life Questionnaire (OPQOL-brief). Items are scored on a five-point scale and coded so that higher scores indicate better quality of life. Total scores range from 13 to 65. Change is the Week 12 score minus the baseline score.
Time frame: Baseline (Week 0) and Week 12
Plan to share: No — Individual participant-level data will not be shared outside the study team due to participant privacy and confidentiality considerations.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 4 months is below that.
Counting every sponsor, half of 518 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.